hrcak mascot   Srce   HID

Ostalo

Lymphedema after Breast and Gynecological Cancer – a Frequent, Chronic, Disabling Condition in Cancer Survivors

Tanja Planinšeg Ručigaj ; Department of Dermatovenereology, University Medical Centre Ljubljana, Zaloška 2, SI-1525 Ljubljana, Slovenia
Vesna Tlaker Žunter

Puni tekst: engleski, PDF (171 KB) str. 101-101 preuzimanja: 289* citiraj
APA 6th Edition
Planinšeg Ručigaj, T. i Tlaker Žunter, V. (2015). Lymphedema after Breast and Gynecological Cancer – a Frequent, Chronic, Disabling Condition in Cancer Survivors. Acta Dermatovenerologica Croatica, 23 (2), 101-101. Preuzeto s https://hrcak.srce.hr/142138
MLA 8th Edition
Planinšeg Ručigaj, Tanja i Vesna Tlaker Žunter. "Lymphedema after Breast and Gynecological Cancer – a Frequent, Chronic, Disabling Condition in Cancer Survivors." Acta Dermatovenerologica Croatica, vol. 23, br. 2, 2015, str. 101-101. https://hrcak.srce.hr/142138. Citirano 25.10.2021.
Chicago 17th Edition
Planinšeg Ručigaj, Tanja i Vesna Tlaker Žunter. "Lymphedema after Breast and Gynecological Cancer – a Frequent, Chronic, Disabling Condition in Cancer Survivors." Acta Dermatovenerologica Croatica 23, br. 2 (2015): 101-101. https://hrcak.srce.hr/142138
Harvard
Planinšeg Ručigaj, T., i Tlaker Žunter, V. (2015). 'Lymphedema after Breast and Gynecological Cancer – a Frequent, Chronic, Disabling Condition in Cancer Survivors', Acta Dermatovenerologica Croatica, 23(2), str. 101-101. Preuzeto s: https://hrcak.srce.hr/142138 (Datum pristupa: 25.10.2021.)
Vancouver
Planinšeg Ručigaj T, Tlaker Žunter V. Lymphedema after Breast and Gynecological Cancer – a Frequent, Chronic, Disabling Condition in Cancer Survivors. Acta Dermatovenerol Croat. [Internet]. 2015 [pristupljeno 25.10.2021.];23(2):101-101. Dostupno na: https://hrcak.srce.hr/142138
IEEE
T. Planinšeg Ručigaj i V. Tlaker Žunter, "Lymphedema after Breast and Gynecological Cancer – a Frequent, Chronic, Disabling Condition in Cancer Survivors", Acta Dermatovenerologica Croatica, vol.23, br. 2, str. 101-101, 2015. [Online]. Dostupno na: https://hrcak.srce.hr/142138. [Citirano: 25.10.2021.]

Sažetak

ABSTRACT The goal of our study was to determine clinical characteristics of women cancer survivors treated for secondary lymphedema, the time from cancer treatment to the development of lymphedema, and the effect of therapy on reduction of lymphedema and occurrence of erysipelas.

We performed a retrospective study of women with secondary lymphedema after breast cancer (BR) and gynecological (cervical, uterine, ovarian, vulvar) cancers (GYN) treated at our Department from 2004 to 2010.

The average time from cancer treatment to the development of lymphedema in our patients was 2.2 and 4.75 years in the BR and GYN groups, respectively, ranging from within days after the procedure to as long as 31 years. The duration of lymphedema in our patients before they first received appropriate therapy was on average 4.1 and 2.65 years in the BR and GYN groups, respectively. In our series, untreated lymphedema was a strong predisposing risk factor for erysipelas, whereas no cases of erysipelas were noticed after the establishment of therapy. Compression therapy was shown to be an effective measure to reduce lymphedema. The duration of required initial decongesting therapy with short-stretch elastic bandages was longer in patients with more long-standing edema.

Lymphedema may first appear several years after the cancer procedure. Our findings emphasize the need for awareness of lymphedema as a possible long-term iatrogenic complication in cancer survivors to avoid a delay in diagnosis and therapy. Physicians in care of cancer survivors should actively look for lymphedema. Untreated lymphedema is a strong predisposing risk factor for erysipelas.

KEY WORDS: secondary lymphedema; cancer therapy side effects; erysipelas; compression therapy; short-stretch elastic bandage

Ključne riječi
secondary lymphedema; cancer therapy side effects; erysipelas; compression therapy; short-stretch elastic bandage

Hrčak ID: 142138

URI
https://hrcak.srce.hr/142138

Posjeta: 484 *